You are reading 1 of 15 free-access articles allowed for 30 days
Company: Sanofi Pharma Bristol-Myers Squibb.
Legal category: Prescription. Sport Permitted. Active ingredient: Clopidogrel (as hydrogen sulphate) 300mg. Description: Pink, oblong, film-coated tablet engraved with 300 on one side and 1332 on the other side. Presentation: 300mg-30, €202.48. Indications: This 300mg tablet of clopidogrel is intended for use as a loading dose in patients suffering from acute coronary syndrome including: Non-ST segment elevation acute coronary syndrome (NSTACS) (unstable angina or non-Q wave MI); ST segment elevation acute MI (STEMI) in medically treated patients eligible for thrombolytic therapy.
{openx:269} Pharmacology: Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, and the subsequent ADP-mediated activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation. Dosage: Adult: 300mg loading dose followed by 75mg daily in combination with 75-100mg aspirin daily (NSTACS) or in combination with aspirin +/- thrombolytics (STEMI). Elderly: No loading dose in STEMI patients >75 years. Children: Under 18 years, not recommended. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Severe liver impairment. Active pathological bleeding such as peptic ulcer or intracranial haemorrhage. Special precautions: Monitor carefully for any signs of bleeding including occult bleeding, especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery. Caution with: Patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions, renal impairment, patients with moderate hepatic disease who may have bleeding diatheses. Discontinue 7 days prior to elective surgery. Thrombotic Thrombocytopenic Purpura (TTP) reported very rarely. Not recommended during the first 7 days after acute ischaemic stroke (lack of data). Contains lactose and hydrogenated castor oil. It is preferable not to use clopidogrel during pregnancy as a precautionary measure. Discontinue breastfeeding during treatment. Drug interactions: Oral anticoagulants are not recommended. Caution: ASA, heparin, glycoprotein IIb/IIIa inhibitors, or NSAIDs including Cox-2 inhibitors. Adverse drug reactions: GI Bleeding, bleeding at puncture site, bruising, haematoma, epistaxis, GI disturbance. Full prescribing information and references available from Sanofi Pharma Bristol-Myers Squibb. Telephone: (01) 403 5600. Fax: (01) 4035687. E-mail:IEmedinfo@sanofi-aventis.com
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
By using this website you are consenting to the use of cookies. Irish Medical Times is owned by MPI Media Limited, a member of the Metropolis Group; you can view our privacy and cookies policy here.